Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The impact of alternative care integration strategies on Health Care Networks’ performance in different Latin American health systems (EQUITY-LA II)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Belgium,Brazil,Chile,Mexico,Argentina,Uruguay,Spain,Colombia
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-08-01
End date: 2019-07-31
Duration (months): 72.0
Total project cost (EUR): 7395229.97
EU funding (EUR): 5926937.0
Participants: 9
Project status: CLOSED

Health services fragmentation is one of the main obstacles to effective health care in Latin-America, particularly for chronic diseases. This research builds upon results from Equity-LA (FP7-B-223123) and focuses on one of the most promoted policies to respond to fragmentation in LA, the development of Integrated Health Care Networks (IHN). The general objective is to evaluate the effectiveness of different care integration strategies in improving coordination and quality of care of IHN in different health care systems in Latin America, with particular reference to chronic diseases. Methods: The study adopts a quasi-experimental design, with a participatory action-research approach. In each country, two comparable IHN will be selected -one acting as the intervention and the other as the control area. It is structured in four phases: 1) a base-line study using qualitative and quantitative methods to carry out an initial evaluation of IHN performance; 2) design and implementation of an intervention focused on care coordination and quality of care; and based on health professionals training; 3) evaluation of effectiveness and limitations of interventions and associated contextual factors; and; 4) cross-country comparative analysis and elaboration of tools for getting research into policy. In each country, a research steering committee will be set up to lead the project, composed by health care professionals, managers, users and researchers. Results and relevance: The project will contribute to FP7 Cooperation Work Programme Health (SICA)’s objectives by: 1) generating evidence-based policies to improve integration of care in Latin American countries; 2) strengthening research capacity of all involved institutions in order to enhance knowledge development on care integration in their countries; and by 3) contributing to skills improvement and motivation of health workforce, through training programs aimed at improving care coordination and quality.

Keywords: health care integration,quality of health care,health policy,health services,quantitative and qualitative methods,best practices,capacity building,health workers training
Profiling Responders In Antibody Therapies (PRIAT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Switzerland,Italy,Netherlands,Germany,Germany,United Kingdom,Austria
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2014-10-31
Duration (months): 24.0
Total project cost (EUR): 3879646.98
EU funding (EUR): 2967485.0
Participants: 8
Project status: CLOSED

Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for the differential responses of patients to treatment. This consortium consists of European centres of excellence being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges: Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen. Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This method is based on the observation that HLA molecules in complex with peptides can be detected in the patient blood and that hundreds of HLA-associated peptides can be sequenced by mass spectrometry. The technology will be used for the profiling of responses following antibody treatment for patients with cancer and rheumatoid arthritis, as well as animal models of transplant rejection. This systems biology approach has the potential to revolutionize patient stratification in very short time. Finally, patient selection strategies will be investigated using the clinical-grade immunocytokine (F8-IL10) as an example, monitoring antibody uptake at the site of disease by immuno-PET imaging methodologies at VUMC Amsterdam in collaboration with Philogen.

Keywords: antibody therapeutics,proteomics,hla - peptide complex analysis,clinical trial,patient stratification,cancer,rheumatoid artritis,transplant rejection
Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy (INSERT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,United Kingdom,Hungary,Netherlands,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-03-01
End date: 2017-02-28
Duration (months): 48.0
Total project cost (EUR): 5981463.43
EU funding (EUR): 4600000.0
Participants: 11
Project status: CLOSED

The purpose of the project INSERT is to provide clinically relevant stratification and improved personalized radio-chemo therapy for brain tumour patients using a specifically developed multi-modality imaging tool. The system will also be used for early assessment of treatment efficacy. The initial focus will be on patients with glioma but there is future potential to target a range of tumours in the head and neck region. The proposed system is based on the development of a novel SPECT (Single Photon Emission Computed Tomography) system, suitable for insertion in the bore of an existing MRI (Magnetic Resonance Imaging) system, a cost-effective solution for widespread application. The combined system will allow the simultaneous measurement of anatomical (MRI) and functional (SPECT & MRI) information and the evaluation of their correlation in space and time. The SPECT design will enable acquisition of fast dynamic studies, with possibility for simultaneous measurement using multiple radionuclides (emitting at different energies), a distinct advantage compared to positron emission tomography (PET). This property can allow in-vivo simultaneous visualisation of spectrally resolved molecular and biochemical tumour properties. The stationary SPECT system is based on recently developed innovative gamma-ray detectors made with Silicon Drift Photodetectors, technology that achieves high-spatial resolution and is compatible with MRI thanks to the use of a silicon photodetector instead of photomultiplier tubes. The multi-modality SPECT/MRI imaging here proposed will apply a fully translational, vertical integration of research and development from technology design through preclinical models to clinical validation.

Keywords: radio-chemo therapies,patient stratification,brain tumour,glioma,multi-modality imaging,spect,mri
European Consortium for the Study of a Topical Treatment of iCRVO to prevent Neovascular Glaucoma (STRONG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Portugal,Germany,United Kingdom,France,France,Germany,Israel
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2018-03-31
Duration (months): 66.0
Total project cost (EUR): 4238641.04
EU funding (EUR): 3311206.98
Participants: 8
Project status: CLOSED

Neovascular glaucoma (NVG) is a very aggressive and rare type of glaucoma: yet, it contributes disproportionately to blindness from all eye diseases. NVG is also the second most common cause for the removal of the eye-ball across all eye diseases, usually because of intractable pain. The major cause of NVG is Ischaemic Central Retinal Vein Occlusion (CRVO) leading to neovascularisation, obstruction of aqueous humour outflow and increased intraocular pressure. Today’s therapeutic approaches are insufficient: they include destruction of the retina by coagulation, or off-label anti-VEGF injection into the eye. It is proposed to develop a better treatment by assessing the topical administration of Aganirsen: it is an antisense oligonucleotide able to interrupt the production of Vascular Endothelial Growth Factor, which plays a major role in the pathogenesis of NVG. Aganirsen is developed by GENE SIGNAL, a SME with expertise in topical ophthalmic treatments for orphan diseases, and manufactured by UNITHER. Under the coordination of the Mainz University Medical Center, a Phase II/III randomised, double-masked, 3-group, placebo-controlled trial (STRONG) is therefore presented to assess Aganirsen’s efficacy in reducing the rate of anterior and posterior segment neovascularisation and NVG development after CRVO. Involving 333 subjects within more than 35 clinical sites, the study is operationalized via a disease specific network (EVICR.net) and a contract research organization managed by GENE SIGNAL. The study aims at assessing a new therapeutic approach for iCRVO to prevent NVG for which conditional authorization will be sought at the end of the project. STRONG also delivers new insights into the natural course of the disease and its risk factors, analysing one of the largest patient cohorts ever. It also allows for a novel classification of NVG, yields novel image analysis tools, and proposes biomarkers able to differentiate between high- and low-risk patients and drug responders.

Keywords: neovascular glaucoma,blindness,antiangiogenic agent,topical ophthalmic treatment,ophthalmology research infrastructure network
A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches. (EUROSTAM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,France,Czechia,Spain,United Kingdom,Switzerland,Greece,Belgium,Sweden
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2015-11-30
Duration (months): 36.0
Total project cost (EUR): 3737167.2
EU funding (EUR): 2623500.0
Participants: 11
Project status: CLOSED

The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they don’t have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aims of this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.

Keywords: transplantation,highly sensitized patients,acceptable mismatches,hla,antibodies,epitopes,european collaboration.
Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative (FRAILOMIC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Switzerland,Austria,Spain,Germany,United Kingdom,France,France,Italy,Austria,United Kingdom,Germany,France,Sweden,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 15491422.98
EU funding (EUR): 11940343.43
Participants: 28
Project status: CLOSED

The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disability is usually preceded by a condition named frailty that encompasses changes associated with ageing, life styles and chronic diseases. To detect and intervene on it is of outstanding importance to prevent disability, as recovery from disability is unlikely. Recent documents stress the necessity of testing the clinical utility (in terms of risk prediction, diagnosis validity and prognostic significance) of the existing definition of frailty by using combinations of clinical criteria (current definition) and lab Biomarkers (BMs). We will measure the levels of blood and urine omic-based BMs in old people selected from eight cohorts, which include up to 75,000 participants, using standardized and innovative technology (WP1). This figure will allow us to test the research questions with a high power and validity. Combining these lab BMs with clinical BMs, we will develop predictive, diagnostic and prognostic models (WP2), with its modulation by nutrition and physical activity, in general old population and in old people showing some characteristics that confer a high risk for developing frailty (selected cardiovascular risk factors and diseases) (WP4). After that, a selected set of BMs will be validated prospectively (WP3) and assessed to find the best-fitted models (WP4). These models will guide the development of the ready-to-use kits to be implemented in the clinical settings. These kits will be at the center of dissemination and exploitation activities (WP5, WP6). A well-balanced consortium distributed over the individual tasks in the respective work packages will carry it out, with a strong participation of SMEs. In summary, FRAILOMIC is original, relevant, pertinent, feasible, overcome the usual research bottlenecks on Biomarkers, and fits perfectly with the topics addressed by the HEALTH.2012.2.1.1-2 call in human subjects

Keywords: omics,ageing,frailty,disability,biomarkers,validation
Towards Early diagnosis and biomarker validation in Arthritis Management (EURO-TEAM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Switzerland,Netherlands,Sweden,Netherlands,Austria,United Kingdom,Germany,United Kingdom,Germany,United Kingdom,Iceland,Sweden,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2016-10-31
Duration (months): 48.0
Total project cost (EUR): 7609029.6
EU funding (EUR): 5777374.0
Participants: 16
Project status: CLOSED

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early phases of disease. The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. Our consortium will achieve this by developing a collaborative, integrated programme of work that links researchers with key SMEs involved in biomarker development to produce a “personalized predictive bioprofile” for patients destined to develop RA. The Euro-TEAM consortium will deliver a step change in the development of biomarkers and diagnostic kits that are timely, strategically important for European SMEs, and based on a disease (RA) in which concrete genetic and environmental risk factors have already been established. Firstly, it will directly compare biomarkers in the preclinical phases of disease with established markers in the clinical phases. Secondly, it will look beyond the synovium interrogating lymphoid, lung and periodontal tissue in a first-in-class approach to measuring systemic changes in the earliest phases of disease. Thirdly, it will place great emphasis on understanding why synovial inflammation resolves in some individuals and develop biomarkers of this “reverse” phase. Fourthly, it will explore a key cell type (stromal cells) that has been almost completely ignored in current biomarker studies. Finally, it will directly involve patients and other specialists, particularly from the fields of genetics, ethics and patient and public involvement in helping to visualize and communicate risk following a positive biomarker test.

Keywords: rheumatoid arthritis,biomarkers,genetics,inflammation
Patient-centered palliative care pathways in advanced cancer and chronic disease (INSUP-C)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Germany,United Kingdom,Hungary,Belgium,Switzerland,Italy,United Kingdom,Netherlands,United States,Spain
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2016-10-31
Duration (months): 48.0
Total project cost (EUR): 3612505.8
EU funding (EUR): 2911593.5
Participants: 11
Project status: CLOSED

Integrated delivery systems of care, e.g. networks of health organizations and professionals who work together to coordinate services to meet their patients’ needs, are an important way of linking fragmented services and maximizing system efficiency and seamlessness of patient transition. Research increasingly shows that patients with advanced cancer and advanced chronic disease are treated well by integrated palliative care pathways, with comparable quality of care at lower costs. Palliative care involves the multidisciplinary care for patients in the last phase of life-threatening disease and is expected to largely grow due to the ageing of the European population. However, palliative care in Europe is still mostly organized across institutional lines: hospital, home care, hospice. This project aims at the identification of best practices in integrated palliative care with regard to quality of life and quality of care. Mixed methods will be used to identify models for integrated palliative care in Europe and to assess patient/caregiver experiences and perceptions within these pathways at the one hand and organizational, managerial, financial and regulatory aspects of these integrated pathways at the other hand. The project will evaluate existing initiatives for patients with cancer, COPD and CHF, and will deliver recommendations on (requirements for) best practices in integrated palliative care. This will also include recommendations on (changes in) skill mix of health professionals. Results will be disseminated via conferences, articles, and an interactive website including an e-learning module. This project will contribute vastly to the improvement of the (organization of) care for patients with advanced cancer and chronic disease and can be extrapolated to other patients with complex care needs.

Keywords: integrated care,palliative care,best practice,skill mix,efficiency,benchmark,patient-centered care,patient experiences
Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial (HEPAMAB)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Spain,France,Sweden,Portugal,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2017-12-31
Duration (months): 60.0
Total project cost (EUR): 7825522.59
EU funding (EUR): 5986903.0
Participants: 7
Project status: CLOSED

Worldwide, 200 million people are infected with the hepatitis C virus (HCV). An estimated 15 million individuals are living with HCV infection within the EU. The economic, health and societal costs of chronic HCV infection are significant. HCV is the principal cause of death from liver disease and the leading indication for liver transplantation. The only treatment for end-stage liver disease is a liver transplant, yet the transplanted liver becomes rapidly re-infected and is frequently destroyed within 5 years after transplantation. In this cohort of patients current antiviral treatments are too toxic - there is an urgent need to develop safe and effective treatments for use in this setting. Human monoclonal antibodies (MAbs) that target virus entry, are as yet an underutilised and potentially highly effective and safe weapon in the armoury against HCV infection. The consortium has identified MAb leads which, in pre-clinical analyses, potently block HCV infection. HCV exhibits a high degree of genetic and antigenic variability, which enables the virus to escape protective immune responses. Crucially, the lead antibodies identified by the consortium are capable of preventing infection by a wide range of genetically distinct isolates because they target highly conserved epitopes on the virus or host receptor molecules. This limits the chances of virus resistance. Also, each lead antibody targets a unique component of the viral entry pathway, thereby paving the way for powerful combinatorial approaches which maximises clinical potency. HepaMAb harnesses leading expertise in MAb technology, preclinical efficacy and safety testing, biomanufacture and clinical trial to progress at least one anti-viral and one anti-receptor human MAb to phase I/IIa proof of concept clinical trial in the liver transplant setting for the prevention of graft reinfection. We will establish a much-needed therapeutic MAb pipeline for use in this solid organ transplant setting.

Keywords: therapeutic antibodies,liver transplant,hepatitis c virus,monoclonal antibody,antiviral